I In isolated hearts of rabbits, perfusion with (-)-noradrenaline (0.0059 to 5.9 M) resulted in chronotropic and inotropic responses and a shortening of the interval between peak atrial and peak ventricular tensions (the A-V contraction interval). No dysrhythmias developed but at higher concentrations (590 ,uM) 2 out of 7 hearts developed dysrhythmias (extrasystoles).
Introduction
Administration of tricyclic antidepressants is known to be associated with the development of a variety of cardiac changes both in poisoning by these agents and after therapeutic use in man (Freeman, Mundy, Beattie & Ryan, 1969; Fouron & Chicoine, 1971; Williams & Sherter, 1971; Roberts, Mueller & Lauer, 1973) . Concurrent use of sympathomimetic agents or procedures known to increase the levels of endogenous catecholamines appear to exacerbate the cardiotoxicity of the tricyclic antidepressants especially with regard to changes in the ECG. Thus, ECG changes have been observed in response to exercise in patients taking antidepressants (Kristiansen, 1961;  Asberg, Cronholm, Sjoqvist & Tuck, 1970 ) and infusions of sympathomimetics in healthy volunteers treated with imipramine tended to induce dysrhythmias (Boakes, Laurence, Teoh, Barar, Benedikter & Prichard, 1973) . In animals, administration of tricyclic antidepressants in conjunction with noradrenaline has also been shown to produce dysrhythmias both in vivo (Elonen & Mattila, 1972; Elonen, Mattila & Saarnivaara, 1974) and in vitro (perfused rabbit heart) with either exogenous or endogenous noradrenaline (Barth & Muscholl, 1974;  Barth, Manns & Muscholl, 1975) . The mechanism by which these effects are produced is not clear but it has been suggested that the undoubted ability of antidepressants to block the uptake of noradrenaline will sensitize the heart to the dysrhythmogenic action of this catecholamine (Byck, 1976) .
It was originally suggested by Barth & Muscholl in 1974 that the isolated perfused heart of the rabbit stimulated through associated sympathetic nerves might prove a satisfactory model on which to assess the relative cardiotoxicity of antidepressants. A technically simpler modification of this preparation involving administration of exogenous noradrenaline through the perfusate was later used successfully by Barth et al. (1975) in the assessment of the cardiotoxicity of several antidepressants and related drugs. They concluded that among tricyclic drugs the ability to inhibit noradrenaline uptake was related to the incidence of dysrhythmias evoked by noradrenaline but that the two parameters were not causally related. We have used this preparation with several modifications to assess the relative cardiotoxicity of the antidepressants amitriptyline, maprotiline (Maitre, Waldmeier, Greengrass, Jaekel, Sedlacek & DeliniStula, 1975; Reiss, Dubey, Finfgeld, Imhof, Hurzeler, Matussek, Rajagopalan, Raschdorf & Schmid, 1975) and the tetracyclic antidepressant, mianserin (Itil, Polvan & Hsu, 1972; Fell, Quantok & van der Burg, 1973) with special reference to the ability of these compounds to inhibit the uptake of noradrenaline and to predispose to noradrenaline-induced dysrhythmias.
Methods

Cardiotoxicity of the antidepressants
Rabbits of either sex (1.5 to 4.0 kg; New Zealand or Californian White strains) were given heparin injection B.P. (2000 iu) through the ear vein 5 min before they were killed by a blow on the head. The heart was removed and placed in ice-cold physiological saline of the following composition, mM: NaCl 122, KCI 3.8, CaC12 1.25, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25, glucose 5.5, L-ascorbic acid 0.085; and aerated with 5% CO2 in 02. The heart was trimmed and mounted for perfusion through the coronary arteries by the method of Langendorff using a constant flow of 25 ml/min (Watson Marlow Flow inducer) at a temperature of 35.5 'C. Atrial and ventricular tensions were recorded isometrically (Dynamometer UF 1) from threads sewn into the heart tissue according to the 'transverse' method (Fozard & Muscholl, 1971; Barth & Muscholl, 1974) . Heart rate was derived from the ventricular tension record with a Devices Instantaneous Rate-meter and perfusion pressure was monitored constantly. Ventricular tension, atrial tension, heart rate and perfusion pressure were displayed on Devices recorders (M2) and a Lan Oscilloscope (Lan-scope 419A) provided a visual monitor of atrial and ventricular tensions. The last two parameters were also displayed on a Mingograf 34 ink writer set to record at a fast speed on which periodic records were obtained and the time interval between the peak atrial and peak ventricular tensions determined (the A-V contraction interval).
Diastolic atrial and ventricular tensions were adjusted to 1.0 and 6.0 g respectively, the preparations were allowed to equilibrate for 15 min and the values of the above parameters were noted. Perfusion was then continued with physiological saline containing the drug under test for the rest of the experiment and after 15 min the values of the above parameters were again noted. Atrial and ventricular tensions were expressed as a percentage of the initial control values while changes in heart rate and A-V contraction interval were expressed in absolute terms. The preparations were then perfused for 5 min successively with each of several concentrations of (-)-noradrenaline (usually 0.0059, 0.019, 0.059, 0.19, 0.59, 1.9 and 5.9 gM) and any changes in the above parameters were noted 4 min after the start of perfusion. The concentrations of noradrenaline in the perfusion when any dysrhythmia was established was also noted. The experiments with the various drugs were performed in random order and each heart was used for one experiment only.
Uptake of [3H1-(-)-noradrenaline in perfused rabbit heart
Rabbit hearts were prepared as above, allowed to equilibrate for 15 min and were then perfused for a further 15 min with physiological saline containing the drug under test.
[3H]4-)-noradrenaline was then added to the perfusion (0.059 gM; 3.33 nCi/ml) and the effluent from the heart was collected in successive 2 min periods for at least 20 minutes. A 1.0 ml sample of the effluent obtained at each collection period (and 3 x 1.0 ml samples of the un-perfused solution) was mixed with 10 ml of a dioxan-based scintillator (naphthalene 100 g, PPO 7 g, POPOP 0.5 g, methanol 50 ml, dioxan to 1000 ml) and counted for tritium in a Packard 3320 Liquid Scintillation Spectrometer. Correction for quench was made by an external standard channels ratio method. The amount of tritium in the effluent leaving the heart was expressed as a percentage of the amount entering the heart and hence the percentage removal of tritium from the perfusate was obtained and taken as an index of noradrenaline uptake.
Uptake of Snedecor & Cochran (1967) .
Results
Effects of the antidepressants amitriptyline, maprotiline and mianserin alone At the end of the initial equilibration period the values for the recorded parameters in a group of 6 control hearts were: (mean + s.e.) ventricular force 9.8 + 0.8 g, atrial force 0.78 +0.13 g, heart rate 125.0+ 2.2 beats/min, perfusion pressure 31.8+2.1 mmHg (4.23 + 0.28 kPa) and A-V contraction interval (the interval between peak atrial and peak ventricular force) 168.6 + 10.6 milliseconds. The groups of hearts later to be perfused with drug-containing solutions showed no statistically significant differences from the above values.
After a further 15 min perfusion with physiological saline alone, control hearts showed no significant changes in these parameters ( Figure 2 Records of heart rate (HR, beats/min), perfusion pressure (P, mmHg), atrial force (AF, g) and ventricular force (VF, g) from an isolated perfused heart of rabbit which was exposed to maprotiline (MAP, 4.0 IM) for 1 5 min and then perfused for 5 min successively with each of various concentrations of (-)-noradrenaline (1-7, 0.0059, 0.019, 0.059, 0.19, 0.59, 1.9 and 5.9 IM respectively). Note the initial chronotropic and inotropic responses to noradrenaline and the dysrhythmia developing after 30 s perfusion with noradrenaline at a concentration of 1.9 lM. Time marker 60 seconds.
interval but did not change heart rate. Maprotiline (4.8 pNi) also reduced ventricular force but did not change the other parameters in a statistically significant manner. Mianserin (4.8 pM) had no significant effect on ventricular force, atrial force or heart rate but produced a small but statistically significant shortening of the A-V contraction interval.
At a higher concentration (28.8 pM), ventricular force was reduced significantly and a marginal increase in the A-V contraction interval was observed though this latter effect was not statistically significant. All these changes are presented in histogram form in Figure 1 . In none of these experiments was cardiac dysrhythmia observed with the concentrations of the drugs under test. In single experiments however it was found that all three agents were capable of producing cardiac dysrhythmias. When hearts were exposed to step-wise increasing concentrations of the antidepressants (2, 4, 8, 20, 40 and 60 pM) a progressive lengthening of the A-V contraction interval was noted which culminated in a dysrhythmia (amitriptyline 8 ,uM; maprotiline 8 pM; mianserin 60 pM).
Effects of noradrenaline in the presence and absence of the antidepressants When perfused with noradrenaline at concentrations of up to 5.9 pM (the highest used routinely) none of the control hearts developed dysrhythmias but in the presence of the antidepressants, dysrhythmias often developed during perfusion with low concentrations of noradrenaline and, once developed, were maintained for the remainder of the perfusion period. A typical record from an experiment is shown in Figure 2 . Note the initial inotropic and chronotropic responses to low concentrations of noradrenaline and the maintained dysrhythmias developing after 30 s perfusion with noradrenaline at a concentration of 1.9 IM. Six hearts were tested in this way at each of the concentrations of the drugs examined and Figure 3 presents the numbers of hearts which showed dysrhythmias at the various concentrations of noradrenaline used. Control hearts and those perfused with mianserin (4.8 gM) did not develop noradrenaline-induced dysrhythmias, neither did those perfused with low concentrations of amitriptyline (1.0 pM, 3 expts.; 2.0 pM, 1 expt.) but at 4.8 pM, 2 of the hearts developed a dysrhythmia at the lowest concentration of noradrenaline (0.0059 MM) and all 6 were eventually affected. Maprotiline appeared to be marginally less effective in predisposing to noradrenaline-induced dysrhythmias since only 1 of the 6 hearts became dysrhythmic with noradrenaline concentrations up to 0.059 pM but at higher noradrenaline concentrations all were eventually affected. With mianserin (28.8 gM) 4 of the hearts became dysrhythmic eventually but the remaining 2 did not develop a dysrhythmia even at the highest concentration of noradrenaline used routinely (5.9 pM). The broken line represents the results obtained for amitriptyline (4.8 gM) by Barth etal. (1975) .
In addition to producing dysrhythmias, noradrenaline perfusions in the presence of the antidepressants also produced inotropic responses. These could not readily be quantitated since dysrhythmias occurred in many cases and because steady-state responses were rarely seen. The chronotropic response however usually did reach a steady-state and it can be seen that in the case of mianserin (4.8,M; the only solution tested that did not provoke dysrhythmias in the presence of noradrenaline) there was a potentiation of the chronotropic response to noradrenaline in comparison with control tissues (Figure 4) .
Noradrenaline perfusions also affected the A-V contraction interval and the values obtained for this parameter in each heart during perfusion with the various concentrations of noradrenaline are shown in Figure 5 . No attempt has been made to calculate means but it is clear that in control hearts noradrenaline produced a shortening of the A-V contraction interval. Noradrenaline conc inperfusate( pM) Figure 4 Increases in heart rate (beats/min) in rabbit isolated hearts in response to perfusion with various concentrations of (-)-noradrenaline alone Figure 5 Effect of noradrenaline on the A-V contraction interval (interval between peak atrial and peak ventricular tensions; ms) in the presence and absence of the antidepressants. Each line represents an isolated perfused heart of a rabbit and measurements were taken: E, at the end of an equilibration period; D, after 1 5 min perfusion with a drug when appropriate; 1-7, during perfusion with (-)-noradrenaline (0.0059, 0.019, 0.059, 0.19, 0.59, 1.9 and 5.9,M respectively). Lines ending in closed circles indicate that a dysrhythmia developed before the next measurement of the A-V contraction interval could be made.
Effects of the antidepressants on [3H1-(-)-noradrenaline uptake
Measurement of the 3H-content of the effluent from hearts perfused with [3H]-(-)-noradrenaline (0.059 gM) showed that the amounts of tritium apparently 'removed' from the perfusate were very high initially as the H3-content of the perfusate was diluted by mixing with the physiological saline already in the 'dead space' of the apparatus (28 ml). However, in both control and treated hearts a plateau was quickly reached which usually remained constant for the remainder of the experiment (20 minutes). In a single control experiment the amount of noradrenaline in the effluent from the heart was also measured fluorimetrically by a modified trihydroxyindole method applied directly to the perfusate. There was general agreement between the fluorimetric and isotopic methods though the fluorimetric method consistently indicated a greater removal of noradrenaline by the heart than did the isotopic method ( Figure 6 ). The percentage removal of noradrenaline for each control or treated heart was calculated as the average removal over 4 samples (each involving a 2 min collection period) obtained between 6 and 14 min after starting the perfusion with [3Hi-(-)-noradrenaline.
The percentage removed by control hearts (28.4 + 0.7%; n= 7) was taken as 100% uptake and the amounts removed by treated hearts were expressed as a percentage of this uptake. Figure 8 and calculation of the concentration of antidepressant required to produce 50% blockade of the uptake of noradrenaline yields the values shown in Table 1 
OL Discussion
The use of the isolated perfused heart of the rabbit in investigations of antidepressant cardiotoxicity was established by Barth et al. (1975) who investigated the effects of a number of antidepressants in this preparation and the results described here for amitriptyline are in agreement with those obtained by these previous workers. We also found that at 4.8 ,uM, amitriptyline reduced the force of atrial and ventricular systole but had no effect on heart rate and that perfusion with low concentrations of noradrenaline in the presence of amitriptyline gave rise to dysrhythmias.
At equimolar concentrations (4.8 gM) amitriptyline reduced the force of ventricular systole to a greater extent than did maprotiline while mianserin produced no significant change. At 28.8 gM the effects of mianserin on ventricular force were slightly greater than those of amitriptyline and it would appear therefore that mianserin is less potent than either amitriptyline or maprotiline in this respect. The relative ability of the three antidepressants to predispose to noradrenaline-induced dysrhythmias is more difficult to quantitate exactly because of the nature of the experimental design. At equimolar concentrations (4.8 gM) amitriptyline appeared more likely to precipitate dysrhythmias at low concentrations of noradrenaline than did maprotiline and no dysrhythmias developed with mianserin. Even when the concentration of mianserin was increased 6-fold only 4 out of the 6 hearts developed dysrhythmias when perfused with noradrenaline. This is not because mianserin prevents the actions of noradrenaline on the heart as inotropic responses were still seen and the chronotropic response was significantly potentiated compared to control tissues. This latter observation suggests the possibility that mianserin, in common with other antidepressants, can interfere with the uptake of noradrenaline in the periphery as it does in rat brain synaptosomes (Raiteri, Angelini & Bertollini, 1976 Firstly, noradrenaline by itself, even in concentrations some 10,000-fold greater than those needed to produce dysrhythmias in the presence of amitriptyline or maprotiline, only produced dysrhythmias in 2 out of 7 hearts. Complete blockade of noradrenaline uptake by minaserin produced only a 4-fold potentiation in the chronotropic response to noradrenaline and in other tissues complete blockade (Trendelenberg, 1972) .
If the predisposition to noradrenaline-induced dysrhythmias were solely due to blockade of noradrenaline uptake it would be expected that a 50 to 100-fold increase in the concentration of noradrenaline perfused through the heart would, by itself, produce dysrhythmias in all hearts but no such effect was seen. Secondly, in the two hearts which did become dysrhythmic in the presence of high concentrations of noradrenaline, the dysrhythmias involved the production of extrasystoles and there was no evidence of any interference with atrio-ventricular synchronization or lengthening of the A-V contraction interval. In contrast, in hearts exposed to noradrenaline as well as an antidepressant, extrasystoles were rarely seen. Usually the dysrhythmias involved an interference .with atrio-ventricular conduction. It appears therefore that the type of dysrhythmia induced by noradrenaline alone is different from that seen with noradrenaline in the presence of an antidepressant, a feature that would not be expected if the dysrhythmia were simply due to potentiation of the normal effects of noradrenaline. In this context it is interesting to note that the dysrhythmias induced by antidepressants in conscious rabbits were also characterized by atrio-ventricular conduction defects (Elonen et al., 1974) and it may be conceptually more useful to think of noradrenaline predisposing to an antidepressant type of dysrhythmia rather than antidepressants predisposing to noradrenaline dysrhythmias.
The third factor which suggests that blockade of noradrenaline uptake is not solely responsible for the precipitation of dysrhythmias comes from a consideration of the effects on A-V contraction interval. The use of this measurement is fraught with difficulties since it represents the time interval between two mechanical events which may, through alterations in rise time for example, bring about a change in the measured A-V contraction interval which bears little relationship to changes in electrical conduction that may have taken place. Nevertheless noradrenaline shortened the A-V contraction interval in normal hearts and is known to speed atrio-ventricular conduction. A-V contraction interval was increased by amitriptyline alone and this agent is known to increase the P-Q interval in the ECG of the conscious rabbit (Elonen et al., 1974) .
Noradrenaline shortened the A-V contraction interval in normal hearts and also in the presence of mianserin (4.8 gM) though the effect was possibly less marked. In contrast, with both maprotiline and amitriptyline a progressive lengthening of the A-V contraction interval was seen as more concentrated solutions of noradrenaline were applied. Indeed, so long did the A-V contraction interval become in some hearts that the atrial contraction immediately preceding a ventricular contraction did not in fact trigger that contraction, but the next ventricular event. Thus a very long A-V contraction interval could easily be mistaken for a very short A-V contraction interval unless the changes are constantly monitored.
In the presence of mianserin (28.8 gM) 4 hearts showed a lengthening of the A-V contraction interval and developed dysrhythmias while the remaining 2 did not develop dysrhythmias or show any marked lengthening of the A-V contraction interval.
It seems likely therefore that the dysrhythmogenic action of noradrenaline in the presence of the antidepressants cannot be due simply to a blockade of noradrenaline uptake. The primary cause in this preparation would appear to be the ability of these compounds to interfere with the normal effects of noradrenaline on the A-V contraction interval which may be related to the intrinsic ability of the molecular structures involved to produce the effect. The presence of an additional ability to block the uptake of noradrenaline would exacerbate this action as the effective concentration of noradrenaline would be raised but this is not the primary cause of the ability of these compounds to predispose to noradrenalineinduced dysrhythmias.
Any extrapolation of these results to the clinical situation in man must be done with extreme caution. Quite apart from any species variation and the fact that the experiments described above do not involve chronic administration, the effects of vagal and other influences on the heart in vivo may grossly modify the effects observed. Furthermore, plasma levels of amitriptyline may approach 300 ng/ml in clinical use (Braithwaite & Widdop, 1971; J0rgensen, 1975) and may be much higher in poisoning but allowing for 95% plasma binding (Borg&, Azarnoff, Forshell & Sjovist, 1969) this represents a free drug concentration of 50 nm, some 100-fold below the concentration used to predispose to dysrhythmias in these experiments.
